mart-1 adenovirus-transduced dendritic cells

MART-1 adenovirus-transduced dendritic cells are an autologous cellular immunotherapy designed to treat patients with MART-1-positive malignancies, primarily metastatic melanoma. This therapeutic approach involves harvesting peripheral blood mononuclear cells from a patient, which are then differentiated ex vivo into mature dendritic cells. These cells are subsequently transduced with a replication-deficient adenoviral vector carrying the gene for the Melanoma Antigen Recognized by T cells-1 (MART-1), also known as Melan-A. When re-infused into the patient, these genetically modified dendritic cells serve as potent antigen-presenting cells that process and display MART-1 epitopes via MHC Class I and II molecules. This presentation primes and activates a robust, antigen-specific cytotoxic T-lymphocyte (CTL) response and helper T-cell response aimed at recognizing and destroying melanoma cells that overexpress the MART-1 differentiation antigen.

Other names

Ad-MART-1 DCAd-MART1 DCAd-MART 1 DCadenoviral MART-1-transduced dendritic cellsMART-1-transduced autologous dendritic cellsMART1-transduced autologous dendritic cellsMART 1-transduced autologous dendritic cellsadenovirus-transduced MART-1 dendritic cell vaccine